Insigneo Advisory Services LLC Buys 1,254 Shares of Novo Nordisk A/S (NYSE:NVO)

Insigneo Advisory Services LLC increased its position in Novo Nordisk A/S (NYSE:NVO) by 11.7% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 11,947 shares of the company’s stock after acquiring an additional 1,254 shares during the quarter. Insigneo Advisory Services LLC’s holdings in Novo Nordisk A/S were worth $1,423,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Kovitz Investment Group Partners LLC grew its holdings in Novo Nordisk A/S by 106.9% during the 3rd quarter. Kovitz Investment Group Partners LLC now owns 82,054 shares of the company’s stock valued at $8,961,000 after buying an additional 42,389 shares in the last quarter. Wellington Management Group LLP bought a new position in shares of Novo Nordisk A/S during the third quarter worth $42,017,000. Wexford Capital LP grew its stake in Novo Nordisk A/S by 170.1% during the third quarter. Wexford Capital LP now owns 7,000 shares of the company’s stock valued at $833,000 after acquiring an additional 4,408 shares in the last quarter. Stansberry Asset Management LLC increased its holdings in Novo Nordisk A/S by 5.3% in the 3rd quarter. Stansberry Asset Management LLC now owns 62,423 shares of the company’s stock valued at $7,433,000 after acquiring an additional 3,142 shares during the last quarter. Finally, Quantinno Capital Management LP lifted its stake in Novo Nordisk A/S by 9.2% in the 3rd quarter. Quantinno Capital Management LP now owns 201,981 shares of the company’s stock worth $24,050,000 after purchasing an additional 16,995 shares in the last quarter. Institutional investors own 11.54% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on NVO shares. StockNews.com raised Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a report on Friday, November 1st. BNP Paribas upgraded Novo Nordisk A/S to a “strong-buy” rating in a report on Monday, December 2nd. Cantor Fitzgerald reissued an “overweight” rating and issued a $160.00 price objective on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. Finally, BMO Capital Markets dropped their price target on Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating on the stock in a research report on Thursday, October 17th. One investment analyst has rated the stock with a hold rating, five have given a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, Novo Nordisk A/S presently has an average rating of “Buy” and a consensus target price of $150.40.

Novo Nordisk A/S Price Performance

NYSE:NVO opened at $110.78 on Friday. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.94 and a quick ratio of 0.75. The company has a 50 day moving average price of $111.51 and a 200-day moving average price of $127.33. Novo Nordisk A/S has a 1-year low of $94.73 and a 1-year high of $148.15. The firm has a market cap of $497.13 billion, a price-to-earnings ratio of 35.85, a price-to-earnings-growth ratio of 1.38 and a beta of 0.40.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.